ReviewTherapeutic advances in neurological disorders2024

Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis.

Maria-Ioanna Stefanou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.